Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$12.12 USD

12.12
3,845,017

-0.23 (-1.86%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $12.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients

by Zacks Equity Research

Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.

NuVasive Gets FDA Nod for CoRoent Small Interlock System

by Zacks Equity Research

NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

by Zacks Equity Research

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

EYE vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

EYE vs. LMAT: Which Stock Is the Better Value Option?

National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

by Zacks Equity Research

National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

National Vision (EYE) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 50.00% and 1.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Reports Next Week: What You Should Expect

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EYE vs. LMAT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EYE vs. LMAT: Which Stock Is the Better Value Option?

GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

by Zacks Equity Research

We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

National Vision (EYE) Down 11.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Innovation Aids Genomic Health, Merger Procedure on Track

by Zacks Equity Research

Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Insulet (PODD) has various favorable factors to maintain the current high.

National Vision's Store Launches on Track Despite Cost Woes

by Zacks Equity Research

National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.

Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety

by Zacks Equity Research

Neogen's (NEOG) proprietary testing platform gets upgraded to reduce the incidence of bacterial contamination in livestock.

NuVasive's New TLIF Implant Broadens Spine Surgery Option

by Zacks Equity Research

NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.

EYE vs. HAE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EYE vs. HAE: Which Stock Is the Better Value Option?

Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod

by Zacks Equity Research

Boston Scientific's (BSX) Vercise Gevia DBS system should boost neuromodulation revenues for the company.

Baxter (BAX) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.

National Vision (EYE) Q2 Earnings Miss Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of -4.76% and 1.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Q2 Earnings Preview: What's in the Cards?

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is National Vision (EYE) Down 4.7% Since Last Earnings Report?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision's (EYE) Q1 Earnings Beat, Margins Decline

by Zacks Equity Research

National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.

National Vision (EYE) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 3.13% and 1.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?